| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2010) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN Prodrug |
| ATC: | B01AE07 |
| UNII: | 2E18WX195X |
| InChI Key | KSGXQBZTULBEEQ-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C34H41N7O5 |
| Molecular Weight | 627.75 |
| AlogP | 5.6 |
| Hydrogen Bond Acceptor | 9.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 15.0 |
| Polar Surface Area | 154.03 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 4.0 |
| Heavy Atoms | 46.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Protease
Serine protease
Serine protease PA clan
Serine protease S1A subfamily
|
- | 3-3 | - | 5 | - | |
|
Enzyme
Protease
Serine protease
|
- | 3-3 | - | 5 | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Thrombosis | 4 | D013927 | ClinicalTrials |
| Venous Thrombosis | 3 | D020246 | ClinicalTrials |
| Thromboembolism | 3 | D013923 | ClinicalTrials |
| Atrial Fibrillation | 3 | D001281 | ClinicalTrials |
| Stroke | 3 | D020521 | ClinicalTrials |
| Venous Thromboembolism | 3 | D054556 | ClinicalTrials |
| Coronary Disease | 2 | D003327 | ClinicalTrials |
| Hematologic Diseases | 1 | D006402 | ClinicalTrials |
| Renal Insufficiency | 1 | D051437 | ClinicalTrials |
| Non-alcoholic Fatty Liver Disease | 1 | D065626 | ClinicalTrials |
| Prostatic Neoplasms | 1 | D011471 | ClinicalTrials |
| Renal Insufficiency, Chronic | 1 | D051436 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 211915-06-9 |
| ChEBI | 70746 |
| ChEMBL | CHEMBL539697 |
| DrugBank | DB06695 |
| DrugCentral | 776 |
| EPA CompTox | DTXSID4057681 |
| FDA SRS | 2E18WX195X |
| Human Metabolome Database | HMDB0015641 |
| Guide to Pharmacology | 6379 |
| PharmGKB | PA165958369 |
| PubChem | 213023 |
| SureChEMBL | SCHEMBL505829 |
| ZINC | ZINC000003943279 |